IHL
Click for more information
0.00% 4.1¢ incannex healthcare limited

Mad to think despite the tirzepatide phase II efficacy results...

  1. Sodono
    23 Posts.
    lightbulb Created with Sketch. 1
    clock Created with Sketch.
    26/06/24
    19:48
    Post #: 74499484
    Mad to think despite the tirzepatide phase II efficacy results being lower than those of 42X and with a comparatively long list of side effects, the news still dropped ResMed's share price by over 10%
    IHL Price at posting: 4.1¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 3  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

SXL Southern Cross says no to buy up of Australian Community Media assets
right-arrow Created with Sketch.
NIM Nimy extends sulphide targets at Mons with new anomalies identified
right-arrow Created with Sketch.
LYC Lynas eyes first dysprosium, terbium HREE production in CY25
right-arrow Created with Sketch.
SVL Silver Mines models five new calderas close to 396Moz Bowdens deposit
right-arrow Created with Sketch.
3DP Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios
right-arrow Created with Sketch.
RMS Ramelius boosts WA gold portfolio with stake in Spartan
right-arrow Created with Sketch.
watchlist Created with Sketch. Add IHL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.